Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 27, 2006. The report details a specific corporate action regarding the repurchase of the company's own shares, executed under authority granted by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 675,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,470.34 pence per share.
- Treasury Shares Held: 176,101,678 shares (post-transaction).
- Shares in Issue: 5,807,424,683 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company purchased 675,000 shares on June 27, 2006, and intends to hold them in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
This filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It is a procedural announcement of a share transaction. The text explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total cost of the repurchase by multiplying 675,000 shares by 1,470.34 pence.
- Confirm the updated total share count (5,807,424,683) against subsequent filings to ensure no further buybacks occurred.
- Review the Annual General Meeting minutes from May 17, 2006, to understand the full scope of the authorized buyback program.
- Check for separate financial reports (e.g., Form 20-F or interim results) for actual revenue and profit data, as this filing does not contain them.